^
Association details:
| Biomarker: | FGFR2-BICC1 fusion |
|---|---|
| Cancer: | Cholangiocarcinoma |
| Drug: | sorafenib (Multi-tyrosine kinase inhibitor, pan-RAF inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
FGFR2-BICC1: A Subtype Of FGFR2 Oncogenic Fusion Variant In Cholangiocarcinoma And The Response To Sorafenib
Excerpt:
A 76-year-old female diagnosed with cholangiocarcinoma underwent four cycles of chemotherapy. The NGS assay showed that the tumor had a FGFR2-BICC1 rearrangement...the patient underwent oral sorafenib treatment in November 2018....According to RECIST, the patient was considered to have a partial response (PR) to sorafenib (Figure 1D)....Up to last follow-up, the disease is stable and the patient is being treated with sorafenib.
DOI:
10.2147/OTT.S218796
